tiprankstipranks
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
US Market

Relmada Therapeutics (RLMD) Income Statement

Compare
333 Followers

Relmada Therapeutics Income Statement

Last quarter (Q3 2024), Relmada Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Relmada Therapeutics's net income was $-21.73M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ -1.26K$ -3.75K$ 0.00
Operating Expenses
$ 103.70M$ 161.25M$ 125.70M$ 60.84M$ 15.11M
Depreciation and Amortization
$ 103.70M$ 2.00K$ 1.26K$ 3.75K$ 4.36K
EBITDA
$ 4.91M$ -157.04M$ -125.75M$ -59.45M$ -15.10M
Operating Income
$ -103.70M$ -161.25M$ -125.70M$ -60.84M$ -15.11M
Other Income/Expenses
$ 4.91M$ 4.21M$ -48.32K$ 1.38M$ 104.11K
Pretax Income
$ -98.79M$ -157.04M$ -125.75M$ -59.46M$ -15.01M
Net Income
$ -98.79M$ -157.04M$ -125.75M$ -59.46M$ -15.01M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -3.28$ -5.30$ -7.16$ -3.81$ -1.63
Diluted EPS
$ -3.28$ -5.30$ -7.16$ -3.81$ -1.63
Weighted Average Shares Outstanding
30.10M 29.63M 17.55M 15.59M 9.23M
Weighted Average Shares Outstanding (Diluted)
30.10M 29.63M 17.55M 15.59M 9.23M
Currency in USD

Relmada Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis